Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis

Davor Vukadinović, Lucas Lauder, David E. Kandzari, Deepak L. Bhatt, Ajay J. Kirtane, Elazer R. Edelman, Roland E. Schmieder, Michel Azizi, M. Böhm, Felix MahfoudCirculation 2024 · DOI

Abstract

Catheter-based renal denervation (RDN) safely reduces ambulatory and office systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to sham procedures, regardless of whether patients are concurrently taking antihypertensive medications.

Introduction

Hypertension remains a leading global cause of cardiovascular morbidity and mortality. Despite a robust pharmacopeia of antihypertensive agents, many patients fail to achieve target blood pressure levels. This failure is often attributed to poor medication adherence or "resistant" hypertension—cases that do not respond sufficiently even to triple-drug regimens.

Renal denervation (RDN), a minimally invasive procedure that disrupts sympathetic nerves near the kidneys using a catheter, was initially proposed as a definitive solution for these patients. However, the field faced a significant setback in 2014 when the SYMPLICITY HTN-3 trial failed to demonstrate a significant benefit over a sham procedure. Since then, the development of second-generation devices and more rigorous trial designs has revitalized interest in the procedure. This systematic review and meta-analysis provides a comprehensive "state-of-the-union" on RDN, evaluating its efficacy and safety across the latest high-quality clinical evidence.

Methods

The authors conducted a systematic review and meta-analysis of randomized, sham-controlled trials (RCTs) published between January 2000 and January 2024. To ensure the highest level of evidence, the study focused on "high-quality" trials as defined by the European Society of Cardiology (ESC).

The primary comparison was RDN versus a sham procedure—a critical control where patients undergo the same catheterization process without the actual nerve ablation to account for the placebo effect. The analysis utilized a study-level, pairwise, random-effects meta-analysis to account for variations in study design and patient populations. Subgroup analyses were performed to determine if outcomes varied based on medication status (on vs. off medications), device generation, or ablation modality.

Data and Technology Modalities

The analysis synthesized data from 10 high-quality trials involving a total of 2,478 patients. The trials covered three primary ablation technologies:

  • Radiofrequency (Heat): SYMPLICITY HTN-3, SPYRAL HTN-OFF/ON, Iberis-HTN, and Netrod RDN.
  • Ultrasound (Sound waves): RADIANCE-HTN SOLO, TRIO, and RADIANCE II.
  • Alcohol-mediated (Chemical): TARGET BP OFF-MED and TARGET BP I.

By including recently released data from trials like Netrod and TARGET BP I, the meta-analysis represents the most current landscape of RDN efficacy.

Key Insights

Biological and Clinical Efficacy

A major strength of this analysis is the inclusion of both "off-medication" and "on-medication" trials. The off-medication trials confirmed a pure biological blood pressure-lowering effect of RDN, while the on-medication trials demonstrated its clinical utility as an additive therapy for patients already receiving standard care.

Technology Agnosticism

One of the most significant findings is that the benefit of RDN appears to be technology-agnostic. Whether using radiofrequency, ultrasound, or chemical ablation, the results consistently showed a significant drop in blood pressure. This suggests that the therapeutic mechanism—disrupting the renal sympathetic nerves—is effective regardless of the energy source used.

Safety and Durability

Despite the invasive nature of the procedure, RDN demonstrated an excellent safety profile. There was no significant increase in major adverse events, such as renal artery stenosis, stroke, or a decline in kidney function (eGFR), compared to sham groups. Furthermore, sensitivity analyses using long-term data (up to 36 months) suggest that the blood pressure reduction is durable, mitigating concerns regarding potential nerve reinnervation over time.

Quantitative Results

The meta-analysis revealed a clear and statistically significant advantage for RDN over sham procedures:

  • 24-Hour Ambulatory SBP: Reduced by 4.4 mmHg (p < 0.00001).
  • Office SBP: Reduced by 6.6 mmHg (p < 0.0001).
  • Diastolic BP: Paralleled systolic findings with reductions of 2.6 mmHg (24-hour) and 3.5 mmHg (office).
  • Medication Interaction: The reduction in SBP was consistent regardless of concomitant medication use (p for interaction = 0.62).
  • Safety Odds Ratios (OR): Vascular complications (OR 1.69, p=0.34) and all-cause death (OR 1.76, p=0.50) were statistically similar between the RDN and sham groups.

Limitations and Future Directions

While the results are compelling, the study has limitations. The use of study-level data rather than individual patient data prevents a granular analysis of which specific patient phenotypes (e.g., age, ethnicity, or comorbidities) respond best to RDN. Additionally, significant statistical heterogeneity was observed between trials, likely due to differences in procedural techniques and patient selection across different regions (notably in trials conducted in China).

While the safety profile is reassuring, the total cohort of 2,478 patients may still be insufficient to detect very rare procedural complications. Future research should focus on identifying "predictors of response" to help clinicians select the patients most likely to benefit from this intervention, moving toward a more personalized approach to hypertension management.

Summary updated

Abstract

RDN safely reduces ambulatory and office systolic blood pressure/diastolic blood pressure versus a sham procedure in the presence and absence of antihypertensive medications.
BibTeX
@inproceedings{vukadinovic2024effects,
  author = {Davor Vukadinović and Lucas Lauder and David E. Kandzari and Deepak L. Bhatt and Ajay J. Kirtane and Elazer R. Edelman and Roland E. Schmieder and Michel Azizi and M. Böhm and Felix Mahfoud},
  title = {{Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis}},
  booktitle = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.124.069709},
}
Figure